NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
Inovio Pharmaceuticals
National Cancer Institute (NCI)
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Novartis
Dana-Farber Cancer Institute
St. Joseph's Hospital and Medical Center, Phoenix
NRG Oncology
Debiopharm International SA
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Jonsson Comprehensive Cancer Center